Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsVentura County Invirase Prior Auth | OpenPayer
    Ask Trek AI about this page
    RetiredVentura County Health Care PlanPolicy N/A

    Invirase (saquinavir) Prior Authorization

    Customize your policy alerts

    Sign up for all venturacountyhealthcareplan policy alerts

    Know when venturacountyhealthcareplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and clinical requirements for Invirase (saquinavir) used to treat HIV-1 infection. It applies to providers requesting coverage through Ventura County Health Care Plan.

    Policy Summary
    PayerVentura County Health Care Plan
    PolicyInvirase (saquinavir) Prior Authorization
    Policy CodePolicy N/A
    Change TypeNo material changearchived
    Effective DateJan 28, 2014
    Last ReviewAug 3, 2021
    Next Review DateN/A
    Key ActionSubmit documentation of a pretreatment EKG, including the QT interval, before therapy is initiated.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    HIV-1Covered treatment indication
    >450 msecPretreatment QT interval that precludes initiation
    1,000 mg BIDAdult saquinavir dose
    100 mg BIDConcomitant ritonavir dose
    >16 years

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Pediatric patients directed to adult dosing

    Coverage Criteria

    Initial Therapy

    Covered when ALL of the following criteria are met:

    ALL of the following

    • The patient has an HIV-1 infection requiring treatment with Invirase (saquinavir).
    • Invirase is prescribed for use in combination with ritonavir; it may also be used with other antiretroviral agents.
    • A pretreatment EKG has been performed and the QT interval is not greater than 450 msec.QT interval ≤450 msec
    • Invirase is prescribed by an Immunology Clinic physician with current American Academy of HIV Medicine (AAHIVM) certification or by a physician boarded in Infectious Disease.

    Continuation Therapy

    Continuation therapy is covered when the patient continues to demonstrate a clinical response to therapy.

    ALL of the following

    • Viral suppression response to Invirase therapy is maintained.
    • Therapy is discontinued promptly if viral suppression response is lost, because continuation may increase the likelihood of cross-resistance to other protease inhibitors.

    Invirase must be used concomitantly with ritonavir. Do not initiate therapy if the pretreatment EKG reveals a QT interval greater than 450 msec.

    Invirase is contraindicated in patients with hypersensitivity to saquinavir or any component of the formulation; congenital or acquired QT prolongation; refractory hypokalemia or hypomagnesemia; concomitant use of other medications that both increase saquinavir plasma concentrations and prolong the QT interval; complete AV block without an implanted ventricular pacemaker or patients at high risk of complete AV block; or severe hepatic impairment.

    Coadministration of saquinavir/ritonavir is contraindicated with alfuzosin, amiodarone, bepridil, cisapride, dofetilide, ergot derivatives, flecainide, systemic lidocaine, lovastatin, oral midazolam, pimozide, propafenone, quinidine, rifampin, sildenafil when used for pulmonary artery hypertension (for example, Revatio), simvastatin, trazodone, or triazolam.

    Clinical and Coding Requirements

    Pretreatment QT interval
    Pretreatment QT intervalMust not exceed 450 msec
    Required screeningComplete a pretreatment EKG, including the QT interval, before initiating therapy
    Initiation restrictionDo not initiate Invirase if the pretreatment QT interval is greater than 450 msec

    Provider Authorization Requirements

    Documentation Required

    HIV-1 Treatment With Ritonavir

    Prior authorization requires documentation that Invirase is being used to treat HIV-1 infection and in combination with ritonavir. It may also be used with other antiretroviral agents.

    • Document the HIV-1 diagnosis and concomitant ritonavir use.
    • Document any additional antiretroviral agents used with Invirase.
    Prior Authorization

    Specialist Prescribing Requirement

    Invirase must be prescribed by a qualified specialist through an Immunology Clinic or by a physician boarded in Infectious Disease.

    • Prescriber must be an Immunology Clinic physician or a board-certified Infectious Disease physician.

    Unsupported block type: documentation

    Clinical Background

    Invirase (saquinavir) is an antiretroviral protease inhibitor used to treat HIV-1 infection. It inhibits HIV-1 protease-mediated cleavage of viral polyprotein precursors, resulting in immature, noninfectious viral particles. Saquinavir must be administered with ritonavir and may be combined with other antiretroviral agents.

    Initial Therapy Criteria

    Initial Authorization

    Initial therapy requires all of the following:

    Initial authorization requirements: Invirase is used for treatment of HIV-1 infection in combination with ritonavir; pretreatment EKG screening is completed with a QT interval no greater than 450 msec; and the prescription is written by a qualified Immunology Clinic or Infectious Disease physician.QT interval <=450 msec

    Other antiretroviral agents may also be included.

    Continuation Criteria

    Continuation After Response

    Continue only when clinical response is maintained:

    Maintained viral suppression: Viral suppression response remains present during therapy.

    Discontinue promptly if viral suppression response is lost, because continued therapy may increase the likelihood of cross-resistance to other protease inhibitors.

    Policy Summary
    PayerVentura County Health Care Plan
    PolicyInvirase (saquinavir) Prior Authorization
    Policy CodePolicy N/A
    Change TypeNo material changearchived
    Effective DateJan 28, 2014
    Last ReviewAug 3, 2021
    Next Review DateN/A
    Key ActionSubmit documentation of a pretreatment EKG, including the QT interval, before therapy is initiated.
    SourceLink
    On This Page
    Coverage CriteriaClinical and Coding RequirementsProvider Authorization RequirementsClinical BackgroundInitial Therapy CriteriaContinuation Criteria
    Prior Authorization

    Qualified Prescriber

    The prescribing physician must hold current American Academy of HIV Medicine (AAHIVM) certification or be boarded in Infectious Disease.

    • Acceptable qualification: current AAHIVM certification for an Immunology Clinic physician.
    • Acceptable qualification: board certification in Infectious Disease.
    Documentation Required

    Medication Guide Required

    Dispense the FDA-approved patient medication guide with Invirase. The guide is available with the product information and from the FDA.

    • FDA medication guide: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM229206.pdf
    Denial Risk

    Exclusion Conditions

    Coverage is excluded when Invirase is not used concomitantly with ritonavir or when the pretreatment EKG shows a QT interval greater than 450 msec. Discontinue therapy promptly if viral suppression response is lost because continued treatment may increase the likelihood of cross-resistance to other protease inhibitors.

    • Exclude therapy without concomitant ritonavir.
    • Exclude initiation when pretreatment QT interval is >450 msec.
    • Discontinue promptly when viral suppression response is lost.
    Denial Risk

    Contraindications and Interacting Drugs

    Do not use Invirase in patients with the listed contraindications or with prohibited interacting drugs.

    • Hypersensitivity to saquinavir or any formulation component.
    • Congenital or acquired QT prolongation; refractory hypokalemia or hypomagnesemia; concomitant medications that both increase saquinavir plasma concentrations and prolong the QT interval.
    • Complete AV block without an implanted ventricular pacemaker, or high risk of complete AV block.
    • Severe hepatic impairment.
    • Do not coadminister saquinavir/ritonavir with alfuzosin, amiodarone, bepridil, cisapride, dofetilide, ergot derivatives, flecainide, systemic lidocaine, lovastatin, oral midazolam, pimozide, propafenone, quinidine, rifampin, sildenafil when used for pulmonary artery hypertension (e.g., Revatio), simvastatin, trazodone, or triazolam.